Dashboard
Manage Tickers

ABOSAcumen Pharmaceuticals, Inc.

Nasdaq acumenpharm.com


$ 2.31 $ -0.13 (-5.42 %)    

Thursday, 05-Sep-2024 15:15:10 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 459.86 $ 0.43 (0.09 %)
DIA $ 407.95 $ -1.96 (-0.48 %)
SPY $ 548.56 $ -1.34 (-0.24 %)
TLT $ 99.56 $ 0.56 (0.57 %)
GLD $ 232.35 $ 1.92 (0.83 %)
$ 2.27
$ 2.39
$ 2.31 x 100
$ 2.32 x 100
$ 2.30 - $ 2.39
$ 1.81 - $ 5.98
287,953
na
136.38M
$ 0.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-27-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ubs-maintains-buy-on-acumen-pharmaceuticals-lowers-price-target-to-6
UBS Maintains Buy on Acumen Pharmaceutical...
08/15/2024 13:11:29

UBS analyst Colin Bristow maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $14 to $6.

hc-wainwright--co-reiterates-buy-on-acumen-pharmaceuticals-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Acum...
08/14/2024 10:33:55

HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pri...

acumen-pharmaceuticals-q2-2024-gaap-eps-034-misses-028-estimate
Acumen Pharmaceuticals Q2 2024 GAAP EPS $(...
08/13/2024 11:03:58

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate...

acumen-pharmaceuticals-has-dosed-the-first-subject-with-a-subcutaneous-formulation-of-sabirnetug-acu193-in-a-phase-1-pharmacokinetic-comparison-study-to-compare-subcutaneous-and-intravenous-administrations-of-sabirnetug-in-healthy-volunteers
Acumen Pharmaceuticals Has Dosed The First...
07/29/2024 11:11:13

Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patie...

acumen-reported-phase-1-results-for-sabirnetug-in-early-symptomatic-alzheimers-disease-at-alzheimers-association-international-conference
Acumen Reported Phase 1 Results for Sabirn...
07/28/2024 12:59:26

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...

citigroup-initiates-coverage-on-acumen-pharmaceuticals-with-buy-rating-announces-price-target-of-7
Citigroup Initiates Coverage On Acumen Pha...
07/25/2024 21:19:51

Citigroup analyst David Hoang initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announces Pri...

acumen-pharmaceuticals-to-present-patient-experience-and-biomarker-insights-from-phase-1-intercept-ad-study-at-the-alzheimers-association-international-conference-2024
Acumen Pharmaceuticals To Present Patient ...
07/11/2024 12:20:25

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...

hc-wainwright--co-reiterates-buy-on-acumen-pharmaceuticals-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Acum...
05/15/2024 11:19:12

HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pri...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 12:06:42

acumen-pharmaceuticals-q1-2024-gaap-eps-025-beats-027-estimate
Acumen Pharmaceuticals Q1 2024 GAAP EPS $(...
05/14/2024 11:01:13

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate o...

acumen-pharmaceuticals-says-first-patient-dosed-in-altitude-ad-a-phase-2-clinical-trial-of-sabirnetug-in-early-alzheimers-disease
Acumen Pharmaceuticals Says First Patient ...
05/08/2024 12:28:21

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...

Core News & Articles
Watching Eledon Pharmaceuticals, Acumen Ph...
04/18/2024 15:41:59

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-over-300-gains-say-analysts/  

acumen-pharmaceuticals-presents-first-comprehensive-clinical-and-biomarker-data-for-sabirnetug-at-american-academy-of-neurology-2024-annual-meeting
Acumen Pharmaceuticals Presents First Comp...
04/16/2024 12:17:32

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker change...

acumen-pharmaceuticals-collaborates-with-lonza-covering-the-manufacture-of-sabirnetug-acu193-for-alzheimers-disease-for-clinical-development-and-commercialization-if-approved
Acumen Pharmaceuticals Collaborates With L...
04/04/2024 12:03:36

hc-wainwright--co-maintains-buy-on-acumen-pharmaceuticals-maintains-15-price-target
HC Wainwright & Co. Maintains Buy on Acume...
03/27/2024 13:22:02

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pric...

acumen-pharmaceuticals-q4-eps-029-misses-026-estimate
Acumen Pharmaceuticals Q4 EPS $(0.29) Miss...
03/26/2024 13:28:09

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate...

acumen-pharmaceuticals-fy23-eps-108-down-from-106-yoy-cash-cash-equivalents-and-marketable-securities-3061m
Acumen Pharmaceuticals FY23 EPS $(1.08) Do...
03/26/2024 11:08:43

earnings-scheduled-for-march-26-2024
Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

acumen-pharmaceuticalss-earnings-a-preview
Acumen Pharmaceuticals's Earnings: A Preview
03/25/2024 15:02:18

acumen-pharmaceuticals-to-present-deeper-insights-including-fluid-biomarker-data-for-sabirnetug-during-emerging-science-session-at-the-american-academy-of-neurology-annual-meeting
Acumen Pharmaceuticals To Present Deeper I...
03/21/2024 12:07:54

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION